Research Program - Experimental Therapeutics

研究计划 - 实验治疗学

• 批准号: 9924527
• 负责人: Giuseppe Giaccone
• 金额: $ 8.25万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9924527
• 关键词: Address; Adolescent and Young Adult; Adoptive Cell Transfers; Applications Grants; Area; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Survivorship; Catchment Area; Clinic; Clinical; Clinical Drug Development; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Comprehensive Cancer Center; Contracts; County; Data Science; Development; Direct Costs; Disease; District of Columbia; Doctor of Philosophy; Funding; Future; Grant; Guidelines; Health; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hospitals; Immune system; Immunotherapy; Institution; Investigational Therapies; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Meridians; Mission; Molecular; NCI Center for Cancer Research; National Cancer Institute; Nature; Neoplasm Metastasis; New Jersey; Oncology; Paper; Pathway interactions; Patients; Pediatric Hematology; Peer Review; Pharmaceutical Preparations; Phase I Clinical Trials; Prognostic Marker; Publishing; Research; Research Personnel; Resistance; Resource Sharing; Role; Science; Services; Strategic Planning; Stromal Neoplasm; Structure; Surrogate Markers; Therapeutic; Thymic Carcinoma; Translational Research; Underserved Population; Universities; Washington; Work; base; cancer biomarkers; cancer care; cancer diagnosis; cancer prevention; circulating biomarkers; health disparity; immune resistance; instrumentation; investigator-initiated trial; liquid crystal polymer; malignant breast neoplasm; meetings; member; minority health; molecular oncology; nano-string; next generation sequencing; optimal treatments; outcome forecast; personalized immunotherapy; pre-clinical; pre-clinical research; precision medicine; precision oncology; predictive marker; programs; survivorship; trend; tumor microenvironment; tumor progression; underserved minority

ABSTRACT The overall mission of the Experimental Therapeutics Program (ET) is to reduce the burden of cancer through preclinical and early clinical drug development; determine optimal treatment combinations and sequences; identify prognostic, predictive and surrogate markers of efficacy and resistance for active agents and deliver best practices to our catchment area and nationally through strategic collaborations. ET encompasses a combination of preclinical, translational and clinical research, with strong ties to the other programs (Breast Cancer [BC], Cancer Prevention and Control [CPC] and Molecular Oncology [MO]). Given its clinical focus, ET has evolved in concert with recent trends and discoveries that have had an impact in the clinic, such as immunotherapy and precision medicine. Aim 1 is focused on targeting known driver pathways of cancer. Aim 2 is focused on targeting the tumor microenvironment (TME) and the immune system. Aim 3 is focused on developing drugs and biomarkers for cancer diagnosis, prognosis and therapy. Significant accomplishments include completing an investigator-initiated trial (IIT) demonstrating the efficacy of pembrolizumab in thymic carcinoma that is shifting the treatment paradigm and work demonstrating the molecular determinants of immune resistance that are identifying new targets for immunotherapy. ET is led by Giuseppe Giaccone, MD, PhD, former Chief of the National Cancer Institute (NCI) Oncology Branch and a leading expert in lung cancer and experimental therapeutics, and Anton Wellstein, MD, PhD, a pharmacologist whose translational research is focused on tumor stromal interactions and mechanisms of cancer progression to metastasis. The LCCC Consortium is comprised of Georgetown Comprehensive Cancer Center, based in Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and LCCC-NJ catchment areas. ET has 43 members, including translational and clinical researchers, from six departments across the Lombardi Comprehensive Cancer Center (LCCC) consortium institutions. The program is funded by $17.81M ($15.84M LCCC-DC, $1.97M LCCC-NJ) in research funding (annual direct costs) of which $1.3M ($0.98M LCCC-DC, $0.32M LCCC-NJ) is peer-reviewed and $0.86M ($0.54M LCCC-DC, $0.32M LCCC-NJ) is NCI funded. ET members published 578 papers, of which 137 were high impact (impact factor [IF] ≥ 8); 15% interprogrammatic, 23% intraprogrammatic and 48% involving external collaborations with other NCI-designated cancer centers. ET members use all nine LCCC Shared Resources. ET addresses challenges in LCCC’s catchment areas in Washington DC and surrounding counties (LCCC-DC) and Bergen County, New Jersey (LCCC-NJ) by focusing on diseases that are relatively overrepresented, such as pancreatic cancer and lung cancer, and offering research-inspired cancer care to patients, including underserved minorities, throughout these catchment areas.

抽象的 实验治疗计划 (ET) 的总体使命是通过以下方式减轻癌症负担： 临床前和早期临床药物开发；确定最佳治疗组合和顺序； 确定活性药物的疗效和耐药性的预后、预测和替代标志物，并提供最佳效果 通过战略合作在我们的流域和全国范围内开展实践。 临床前、转化和临床研究，与其他项目（乳腺癌 [BC]、 鉴于其临床重点，ET 已在癌症预防和控制 [CPC] 和分子肿瘤学 [MO] 中发展。 与对临床产生影响的最新趋势和发现相一致，例如免疫疗法和 目标 1 侧重于针对已知的癌症驱动途径。 针对肿瘤微环境 (TME) 和免疫系统的目标 3 侧重于开发药物和药物。 癌症诊断、预后和治疗的生物标志物的重大成就包括完成一项研究。 研究人员发起的试验 (IIT) 证明了派姆单抗对正在发生转移的胸腺癌的疗效 治疗范例和工作证明了免疫抵抗的分子决定因素 确定免疫治疗新靶点的工作由医学博士、哲学博士、前首席科学家朱塞佩·贾科内 (Giuseppe Giaccone) 领导。 美国国家癌症研究所 (NCI) 肿瘤科和肺癌和实验领域的领先专家 疗法，以及 Anton Wellstein 医学博士、哲学博士，药理学家，其转化研究重点是肿瘤 间质相互作用和癌症进展至转移的机制由 LCCC 联盟组成。 位于华盛顿特区的乔治城综合癌症中心 (LCCC-DC) 和 John Theurer 位于新泽西州哈肯萨克的 Hackensack Meridian Health 癌症中心 (LCCC-NJ)。 集水区由 LCCC-DC 和 LCCC-NJ 集水区定义，有 43 个成员。 来自隆巴迪综合癌症中心六个部门的转化和临床研究人员 (LCCC) 联盟机构资助该计划 1,781 万美元（LCCC-DC 1,584 万美元，LCCC-NJ 197 万美元）。 研究经费（年度直接费用），其中 130 万美元（98 万美元 LCCC-DC，32 万美元 LCCC-NJ）经过同行评审 86 万美元（54 万美元 LCCC-DC，32 万美元 LCCC-NJ）由 NCI 资助，其中 ET 成员发表了 578 篇论文。 137 个具有高影响力（影响因子 [IF] ≥ 8）；15% 属于计划间，23% 属于计划内，48% 属于涉及 与其他 NCI 指定癌症中心的外部合作使用全部九个 LCCC 共享。 资源 ET 解决华盛顿特区及周边县 LCCC 流域的挑战。 (LCCC-DC) 和新泽西州卑尔根县 (LCCC-NJ) 重点关注相对较轻的疾病 代表性过高，例如胰腺癌和肺癌，并为以下人群提供受研究启发的癌症护理 整个服务区域的患者，包括服务不足的少数族裔。